Technical Analysis for OXBDF - Oxford Biomedical Lt

Grade Last Price % Change Price Change
grade D 6.85 -2.70% -0.1900
OXBDF closed down 2.7 percent on Monday, October 21, 2019, on 2 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical OXBDF trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Down Weakness 0.00%
Crossed Above 20 DMA Bullish -2.70%
Narrow Range Bar Range Contraction -2.70%
Gapped Up Strength -2.70%
Narrow Range Bar Range Contraction 4.42%
Gapped Up Strength 4.42%
Oversold Stochastic Weakness 4.42%
MACD Bullish Signal Line Cross Bullish 6.20%

Older signals for OXBDF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development include OXB-102 that is in Phase I/IIa study preparation for the treatment of Parkinson's disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; and OXB-302, a gene-based cancer immunotherapy product that has completed pre-clinical development for use in the treatment of a range of cancers, as well as OXB-201 that has completed Phase I trial for the treatment of wet age-related macular degeneration and diabetic retinopathy. It is also developing gene-based therapies, such as SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, which is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, and Immune Design. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Branches Of Biology Biopharmaceutical Life Sciences Biology Cancers Immunotherapy Cell Therapy Parkinson's Disease Platform Technology Diabetic Retinopathy Central Nervous System Disorders Treatment Of Parkinson's Disease Gene Therapy Medical Genetics Virotherapy Macular Degeneration Parkinson's Genetic Engineering Cell Therapy Products Treatment Of A Range Of Cancers Treatment Of Various Cancers Applied Genetics
Is OXBDF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 15.15
52 Week Low 0.11
Average Volume 6,177
200-Day Moving Average 7.9353
50-Day Moving Average 8.0539
20-Day Moving Average 6.9151
10-Day Moving Average 6.669
Average True Range 0.2534
ADX 33.35
+DI 37.1839
-DI 50.2693
Chandelier Exit (Long, 3 ATRs ) 7.0398
Chandelier Exit (Short, 3 ATRs ) 6.9602
Upper Bollinger Band 7.8044
Lower Bollinger Band 6.0258
Percent B (%b) 0.46
BandWidth 25.720525
MACD Line -0.3711
MACD Signal Line -0.4501
MACD Histogram 0.0791
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.8500
Resistance 3 (R3) 6.8500 6.8500 6.8500
Resistance 2 (R2) 6.8500 6.8500 6.8500 6.8500
Resistance 1 (R1) 6.8500 6.8500 6.8500 6.8500 6.8500
Pivot Point 6.8500 6.8500 6.8500 6.8500 6.8500
Support 1 (S1) 6.8500 6.8500 6.8500 6.8500 6.8500
Support 2 (S2) 6.8500 6.8500 6.8500 6.8500
Support 3 (S3) 6.8500 6.8500 6.8500
Support 4 (S4) 6.8500